<DOC>
	<DOCNO>NCT01705483</DOCNO>
	<brief_summary>The purpose study determine safety tolerability pharmacokinetics ASP9853 combine docetaxel paclitaxel subject advance non-hematologic malignancy .</brief_summary>
	<brief_title>A Phase 1 , Dose Escalation Study Assess Safety Tolerability ASP9853 With Either Docetaxel Paclitaxel Patients With Advanced Non-hematologic Malignancies</brief_title>
	<detailed_description>This two part study . Part 1 test increase dose level ASP9853 combination docetaxel . Part 2 test increase dos ASP9853 combine paclitaxel . Each part determine maximum tolerate dose recommended Phase 2 dose ASP9853 combination taxane . Preliminary evidence antitumor activity ASP9853 combination docetaxel paclitaxel also explore .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Subject must histologically cytologically confirm incurable , locally advanced , metastatic nonhematologic malignancy progress failed respond regimen therapy know provide clinical benefit Subject must Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 1 Subject must recover effect prior systemic antineoplastic radiation therapy ( ) ≤ Grade 1 severity subject 's baseline value , exclude alopecia Subject agree participate another interventional study treatment Female subject must either : Of non child bear potential : postmenopausal ( define least 1 year without menses ) prior Screening document surgically sterile status post hysterectomy ( least 1 month prior Screening ) Or , childbearing potential : must negative serum pregnancy test Screening must use two form birth control ( least one must barrier method ) start Screening throughout study period 28 day final study drug administration Acceptable form include : Established use oral , injected implant hormonal method contraception . Placement intrauterine device ( IUD ) intrauterine system ( IUS ) . Barrier method contraception : Condom OR Occlusive cap ( diaphragm cervical/vault cap ) spermicidal foam/gel/film/cream/suppository Female subject must donate ovum start Screening throughout study period 28 day final study drug administration . Male subject must donate sperm start Screening throughout study period 28 day final study drug administration . Subject adequate bone marrow , renal , hepatic function baseline Subject receive 3 prior cytotoxic agentcontaining regimen Subjects prior anaphylactic hypersensitivity reaction prior taxane therapy Subject symptomatic central nervous system ( CNS ) metastases leptomeningeal involvement Subjects receive treatment follow : Systemic chemotherapy within 21 day Nitrosoureas mitomycin C within 42 day Radiotherapy ≥ 25 % hematopoietically active bone marrow within 21 day Subject major surgical procedure within 28 day anticipates need major surgical procedure course study Female subject breastfeed Screening study period 28 day final study drug administration . Subject peripheral neuropathy &gt; Grade 1 baseline Subject know hepatitis B surface antigen ( HBsAg ) positive status ; know suspect active hepatitis C infection ; know human immunodeficiency virus ( HIV ) positive Subject malabsorption syndrome disease condition significantly affect gastrointestinal function Subject significant uncontrolled cardiac , renal , hepatic systemic disorder , significant psychological condition baseline Subject clinically significant electrocardiogram ( ECG ) abnormalities 12 lead ECG perform within 14 day start study drug Subject receive strong inhibitor inducer CYP3A4 within two week prior start study treatment study Subject participate interventional clinical study treat investigational drug within 30 day 5 half life , whichever longer , prior initiation Screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>ASP9853</keyword>
	<keyword>Docetaxel</keyword>
	<keyword>Paclitaxel</keyword>
</DOC>